Study: Cook Medical’s Hemospray viable treatment for nonvariceal lower GI bleeds
A new, multicenter study sponsored by Cook Medical on the company's Hemospray Endoscopic Hemostat device showed that the use of Hemospray demonstrated a more than 98 percent successful hemostasis rate, while the 30-day rebleeding rate was 10 percent. These results, said Cook in a news release, provide support for the safety of hemostatic powder when used to treat patients with gastrointestinal bleeding in the lower GI tract.
The study was published in Gastrointestinal Endoscopy. The prospective, nonrandomized, study was conducted at four tertiary care centers in Canada and involved 50 patients with a total of 52 active bleeding sites in the lower gastrointestinal tract. Hemospray is an inert, bentonite powder developed for endoscopic hemostasis and is used for hemostasis of nonvariceal gastrointestinal bleeding.
The study, titled “Successful hemostasis of active lower GI bleeding using a hemostatic powder as monotherapy, combination therapy, or rescue therapy,” was authored by Lawrence Hookey, MD; Alan Barkun, MD; Richard Sultanian, MD; and Robert Bailey, MD. The team concluded that the hemostatic powder is a “safe and effective option for patients with lower GI bleeding of varying causes, and in particular, postpolypectomy hemorrhage.” Hemospray was found to be effective when used as monotherapy, in combination with other treatment and as a rescue therapy.
